相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy
Jeffrey Lazarus et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2020)
Global Epidemiology of Viral Hepatitis
Homie Razavi
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2020)
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
Ilias Gountas et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
Christian Krauth et al.
BMC INFECTIOUS DISEASES (2019)
Efficacy and safety of alisporivir for the treatment of hepatitis C infection
Carol Stanciu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Recombinant Variants of Hepatitis C Virus in Siberia
E. V. Chub et al.
MOLECULAR GENETICS MICROBIOLOGY AND VIROLOGY (2019)
Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland
Sarah Blach et al.
SWISS MEDICAL WEEKLY (2019)
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
Hidenori Toyoda et al.
HEPATOLOGY (2018)
Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals
Navaneethan Palanisamy et al.
ANTIVIRAL THERAPY (2018)
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles et al.
HEPATOLOGY (2018)
High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study
A. Abergel et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
JOURNAL OF HEPATOLOGY (2018)
Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures
Y. Jeong et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
Ralf Bartenschlager et al.
VIRUS RESEARCH (2018)
SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN A GENOTYPE 1-6 HCV INFECTED POPULATION FROM SINGAPORE, MALAYSIA, THAILAND, AND VIETNAM: RESULTS FROM A PHASE 3, CLINICAL TRIAL
Seng Gee Lim et al.
GUT (2018)
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Fasiha Kanwal et al.
GASTROENTEROLOGY (2017)
Eight Weeks of Ledipasvir/Sofosbuvir Is Effective for Selected Patients With Genotype 1 Hepatitis C Virus Infection
Kris V. Kowdley et al.
HEPATOLOGY (2017)
ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis
G. R. Foster et al.
JOURNAL OF HEPATOLOGY (2017)
Efficacy and safety of elbasvir/grazoprevir in treatment-naive patients with chronic HCVGT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial
L. Wei et al.
JOURNAL OF HEPATOLOGY (2017)
Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials
P. Krishnan et al.
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study
J. Rockstroh et al.
JOURNAL OF HEPATOLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir
David Wyles et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns et al.
LANCET INFECTIOUS DISEASES (2017)
Direct-acting antivirals: the endgame for hepatitis C?
Roberta D'Ambrosio et al.
CURRENT OPINION IN VIROLOGY (2017)
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial
Tania M. Welzel et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study
David Wyles et al.
CLINICAL INFECTIOUS DISEASES (2017)
Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues
Jordan J. Feld
CURRENT DRUG TARGETS (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection
Armand Abergel et al.
HEPATOLOGY (2016)
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
Natasha K. Martin et al.
JOURNAL OF HEPATOLOGY (2016)
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J. Dore et al.
JOURNAL OF HEPATOLOGY (2016)
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study
Armand Abergel et al.
LANCET INFECTIOUS DISEASES (2016)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Hepatitis C Virus Therapeutic Development: In Pursuit of Perfectovir
Gregory J. Dore et al.
CLINICAL INFECTIOUS DISEASES (2015)
The hepatitis C revolution part 1: antiviral treatment options
Prarthana Thiagarajan et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2015)
Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2015)
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
K. Rajender Reddy et al.
HEPATOLOGY (2015)
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
Anita Kohli et al.
LANCET INFECTIOUS DISEASES (2015)
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The role of HCV proteins on treatment outcomes
Kattareeya Kumthip et al.
VIROLOGY JOURNAL (2015)
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
Mirjam B. Zeisel et al.
VIRUSES-BASEL (2015)
Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
Auda A. Eltahla et al.
VIRUSES-BASEL (2015)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Juergen K. Rockstroh et al.
LANCET HIV (2015)
HCV direct-acting antiviral agents: the best interferon-free combinations
Raymond Schinazi et al.
LIVER INTERNATIONAL (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Profile of alisporivir and its potential in the treatment of hepatitis C
Philippe A. Gallay et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
The NS5A Replication Complex Inhibitors: Difference Makers?
Robert G. Gish et al.
CLINICS IN LIVER DISEASE (2011)
NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C
Tarik Asselah
JOURNAL OF HEPATOLOGY (2011)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Mark S. Sulkowski et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao et al.
NATURE (2010)
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
D Lamarre et al.
NATURE (2003)
分享论文
